title: Intracerebroventricular injection of leukotriene B4 attenuates antigen-induced asthmatic response via BLT1 receptor stimulating HPA-axis in sensitized rats.
abstract: BACKGROUND
  Basic and clinical studies suggest that hypothalamic-pituitary-adrenal (HPA) axis is the neuroendocrine-immune pathway that functionally regulates the chronic inflammatory disease including asthma. Our previous studies showed corresponding changes of cytokines and leukotriene B4 (LTB4) between brain and lung tissues in antigen-challenged asthmatic rats. Here, we investigated how the increased LTB4 level in brain interacts with HPA axis in regulating antigen-induced asthmatic response in sensitized rats.
  
  
  METHODS
  Ovalbumin-sensitized rats were challenged by inhalation of antigen. Rats received vehicle, LTB4 or U75302 (a selective LTB4 BLT1 receptor inhibitor) was given via intracerebroventricular injection (i.c.v) 30 min before challenge. Lung resistance (RL) and dynamic lung compliance (Cdyn) were measured before and after antigen challenge. Inflammatory response in lung tissue was assessed 24 h after challenge. Expression of CRH mRNA and protein in hypothalamus were evaluated by RT-PCR and Western Blot, and plasma levels of adrenocorticotropic hormone (ACTH) and corticosterone (CORT) were measured using the ELISA kits.
  
  
  RESULTS
  Antigen challenge decreased pulmonary function and induced airway inflammation, evoked HPA axis response in sensitized rats. Administration of LTB4 via i.c.v markedly attenuated airway contraction and inflammation. Meanwhile, LTB4 via i.c.v markedly increased CORT and ACTH level in plasma before antigen challenge, and followed by further increases in CORT and ACTH levels in plasma after antigen challenge in sensitized rats. Expression of CRH mRNA and protein in hypothalamus were also significantly increased by LTB4 via i.c.v in sensitized rats after antigen challenge. These effect were completely blocked by pre-treatment with BLT1 receptor antagonist U75302 (10 ng), but not by BLT2 antagonist LY255283.
  
  
  CONCLUSIONS
  LTB4 administered via i.c.v down-regulates the airway contraction response and inflammation through activation of the HPA axis via its BLT1 receptor. This study expands our concept of the regulatory role of intracranial inflammatory mediators in inflammatory diseases including asthma. The favourable effects of LTB4 on the HPA axis may help to explain the phenomenon of self-relief after an asthmatic attack.
authors.affiliation: Zhejiang Respiratory Drugs Research Laboratory of State Food and Drug Administration of China, Medical Science College of Zhejiang University, Hangzhou, China. zsjdxw@163.com
authors.forename: Shui-Juan
authors.initials: SJ
authors.lastname: Zhang
authors.forename: Yang-Mei
authors.initials: YM
authors.lastname: Deng
authors.forename: Yi-Liang
authors.initials: YL
authors.lastname: Zhu
authors.forename: Xin-Wei
authors.initials: XW
authors.lastname: Dong
authors.forename: Jun-Xia
authors.initials: JX
authors.lastname: Jiang
authors.forename: Qiang-Min
authors.initials: QM
authors.lastname: Xie
mesh_terms: D000324:Adrenocorticotropic Hormone / Q000097:blood; D000403:Airway Resistance; D000818:Animals; D001249:Asthma / Q000276:immunology / Q000378:metabolism* / Q000503:physiopathology; D015153:Blotting, Western; D003346:Corticotropin-Releasing Hormone / Q000235:genetics / Q000378:metabolism; D004195:Disease Models, Animal; D004797:Enzyme-Linked Immunosorbent Assay; D005233:Fatty Alcohols / Q000008:administration & dosage; D005260:Female; D006018:Glycols / Q000008:administration & dosage; D007030:Hypothalamo-Hypophyseal System / Q000187:drug effects / Q000276:immunology / Q000378:metabolism*; D007031:Hypothalamus / Q000276:immunology / Q000378:metabolism; D018836:Inflammation Mediators / Q000378:metabolism; D007276:Injections, Intraventricular; D007975:Leukotriene B4 / Q000008:administration & dosage / Q000378:metabolism*; D008168:Lung / Q000276:immunology / Q000378:metabolism* / Q000503:physiopathology; D008170:Lung Compliance; D008297:Male; D010047:Ovalbumin; D010913:Pituitary-Adrenal System / Q000187:drug effects / Q000276:immunology / Q000378:metabolism*; D011657:Pulmonary Eosinophilia / Q000276:immunology / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D018102:Receptors, Leukotriene B4 / Q000819:agonists / Q000037:antagonists & inhibitors / Q000378:metabolism*; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: D005233:Fatty Alcohols; D006018:Glycols; D018836:Inflammation Mediators; D012333:RNA, Messenger; D018102:Receptors, Leukotriene B4; C062137:U 75302; D007975:Leukotriene B4; D000324:Adrenocorticotropic Hormone; D010047:Ovalbumin; D003346:Corticotropin-Releasing Hormone
references.citation: Exp Dermatol. 2006 Mar;15(3):143-53
references.pmid: 16480421
references.citation: Acta Pharmacol Sin. 2003 Oct;24(10):1039-44
references.pmid: 14531949
references.citation: Allergy. 2009 Jan;64(1):18-31
references.pmid: 19132973
references.citation: J Neurochem. 1996 Jan;66(1):147-52
references.pmid: 8522947
references.citation: Ageing Res Rev. 2006 Aug;5(3):281-309
references.pmid: 16904953
references.citation: Int Immunopharmacol. 2008 Dec 10;8(12):1639-45
references.pmid: 18721904
references.citation: N Engl J Med. 1995 May 18;332(20):1351-62
references.pmid: 7715646
references.citation: J Allergy Clin Immunol. 2004 Oct;114(4):747-54
references.pmid: 15480311
references.citation: Ann Allergy Asthma Immunol. 2007 Mar;98(3):269-73
references.pmid: 17378259
references.citation: Psychosom Med. 2003 Sep-Oct;65(5):811-5
references.pmid: 14508025
references.citation: Neuroimmunomodulation. 2006;13(1):43-50
references.pmid: 16837794
references.citation: Peptides. 2005 Nov;26(11):2252-6
references.pmid: 15978700
references.citation: J Exp Med. 2000 Aug 7;192(3):421-32
references.pmid: 10934230
references.citation: Am J Respir Crit Care Med. 2004 Jan 15;169(2):220-6
references.pmid: 14604839
references.citation: Nature. 1997 Jun 5;387(6633):620-4
references.pmid: 9177352
references.citation: Neuroendocrinology. 1989 Dec;50(6):708-15
references.pmid: 2559344
references.citation: Brain Behav Immun. 2007 May;21(4):384-92
references.pmid: 17198749
references.citation: N Engl J Med. 2007 Nov 1;357(18):1841-54
references.pmid: 17978293
references.citation: J Appl Physiol (1985). 1988 Nov;65(5):2024-9
references.pmid: 2905361
references.citation: Nat Rev Immunol. 2006 Apr;6(4):318-28
references.pmid: 16557263
references.citation: Curr Opin Allergy Clin Immunol. 2010 Feb;10(1):60-6
references.pmid: 19915456
references.citation: J Mol Endocrinol. 2007 Mar;38(3):355-63
references.pmid: 17339398
references.citation: J Immunol. 2004 Jun 1;172(11):7053-9
references.pmid: 15153527
references.citation: J Exp Med. 2001 Jul 2;194(1):71-8
references.pmid: 11435473
references.citation: Neurochem Int. 2008 Jan;52(1-2):40-51
references.pmid: 17716784
references.citation: Brain Res. 1995 Jul 10;685(1-2):201-4
references.pmid: 7583247
references.citation: Acta Pharmacol Sin. 2003 Mar;24(3):277-82
references.pmid: 12617779
references.citation: Ann Allergy Asthma Immunol. 2003 Jun;90(6 Suppl 3):34-40
references.pmid: 12839111
references.citation: Acta Pharmacol Sin. 2005 Mar;26(3):353-8
references.pmid: 15715933
references.citation: Ann N Y Acad Sci. 2009 Feb;1153:220-39
references.pmid: 19236345
references.citation: Vet Immunol Immunopathol. 2009 Aug 15;130(3-4):141-62
references.pmid: 19261335